Early disruption of the blood-brain barrier after thrombolytic therapy predicts hemorrhage in patients with acute stroke. Hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke: mechanisms, models, and biomarkers. Mol Neurobiol ; Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke.
Circulation ; Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci ; Fisher M. New approaches to neuroprotective drug development. Stroke ;42 1 Suppl :SS Reconsidering neuroprotection in the reperfusion era. Update of the stroke therapy academic industry roundtable preclinical recommendations.
Stroke Treatment Academic Industry Roundtable STAIR recommendations for maximizing the use of intravenous thrombolytics and expanding treatment options with intra-arterial and neuroprotective therapies. Matrix metalloproteinase-9 in an exploratory trial of intravenous minocycline for acute ischemic stroke. Stroke ;ee Can adjunctive therapies augment the efficacy of endovascular thrombolysis?
A potential role for activated protein C. Neuropharmacology ; Pt B The effect of combined thrombolysis with rtPA and tirofiban on ischemic brain lesions. Neurology ; Lapchak PA. Tumor necrosis factor-alpha is involved in thrombolytic-induced hemorrhage following embolic strokes in rabbits. Brain Res ; Matrix metalloproteinases inhibition provides neuroprotection against hypoxia-ischemia in the developing brain. J Neurochem ; A broad-spectrum matrix metalloproteinase inhibitor prevents hemorrhagic complications induced by tissue plasminogen activator in mice.
Neuroscience ; Combination treatment with low-dose Niaspan and tissue plasminogen activator provides neuroprotection after embolic stroke in rats. J Neurol Sci ; Inhibition of NF-kappaB activation by pyrrolidine dithiocarbamate prevents in vivo expression of proinflammatory genes. Early administration of pyrrolidine dithiocarbamate extends the therapeutic time window of tissue plasminogen activator in a male rat model of embolic stroke.
J Neurosci Res ; Bryostatin improves survival and reduces ischemic brain injury in aged rats after acute ischemic stroke. Bryostatin extends tPA time window to 6 h following middle cerebral artery occlusion in aged female rats. Eur J Pharmacol ; Inhibition of tPA-induced hemorrhagic transformation involves adenosine A2b receptor activation after cerebral ischemia.
Neurobiol Dis ; Neuroprotective and cognitive enhancement potentials of baicalin: a review. Brain Sci ;8:E Baicalin attenuates blood-brain barrier disruption and hemorrhagic transformation and improves neurological outcome in ischemic stroke rats with delayed t-PA treatment: involvement of ONOO - -MMP-9 pathway. Transl Stroke Res ; Granulocyte colony-stimulating factor attenuates delayed tPA-induced hemorrhagic transformation in ischemic stroke rats by enhancing angiogenesis and vasculogenesis.
Extension of tissue plasminogen activator treatment window by granulocyte-colony stimulating factor in a thromboembolic rat model of stroke. Int J Mol Sci ;E Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke.
Exp Neurol ; Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain ; Pt 6 Extension of the thrombolytic time window with minocycline in experimental stroke. Effects of minocycline plus tissue plasminogen activator combination therapy after focal embolic stroke in type 1 diabetic rats. Minocycline for acute stroke treatment: a systematic review and meta-analysis of randomized clinical trials. J Neurol ; Minocycline treatment in acute stroke: an open-label, evaluator-blinded study.
Efficacy of minocycline in acute ischemic stroke: a single-blinded, placebo-controlled trial. Neurol India ; Efficacy of minocycline in acute ischemic stroke: a systematic review and meta-analysis of rodent and clinical studies. Front Neurol ; Reducing haemorrhagic transformation after thrombolysis for stroke: a strategy utilising minocycline. Stroke Res Treat ; Strategies to extend thrombolytic time window for ischemic stroke treatment: an unmet clinical need.
J Stroke ; Neuroprotectants in the era of reperfusion therapy. Uric acid reduces brain damage and improves the benefits of rt-PA in a rat model of thromboembolic stroke. Uric acid therapy improves the outcomes of stroke patients treated with intravenous tissue plasminogen activator and mechanical thrombectomy. Int J Stroke ; Statins: multiple mechanisms of action in the ischemic brain. Neuroscientist ; The 3-hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin reduces thrombolytic-induced intracerebral hemorrhage in embolized rabbits.
Atorvastatin extends the therapeutic window for tPA to 6 h after the onset of embolic stroke in rats. Combination of thrombolysis and statins in acute stroke is safe: results of the STARS randomized trial stroke treatment with acute reperfusion and simvastatin.
Effect and safety of rosuvastatin in acute ischemic stroke. Dissociation and protection of the neurovascular unit after thrombolysis and reperfusion in ischemic rat brain. Clinical effects of early edaravone use in acute ischemic stroke patients treated by endovascular reperfusion therapy. The impact of recanalization on ischemic stroke outcome: a meta-analysis.
Predictors of early arterial reocclusion after tissue plasminogen activator-induced recanalization in acute ischemic stroke. Clinical deterioration after intravenous recombinant tissue plasminogen activator treatment: a multicenter transcranial Doppler study. Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomized controlled trial.
Systemic thrombolysis with recombinant tissue plasminogen activator and tirofiban in acute middle cerebral artery occlusion. Safety and preliminary efficacy of early tirofiban treatment after alteplase in acute ischemic stroke patients. In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator. Circ Res ; Extension of the therapeutic window for recombinant tissue plasminogen activator with argatroban in a rat model of embolic stroke.
The argatroban and tissue-type plasminogen activator stroke study: final results of a pilot safety study. J Stroke Cerebrovasc Dis ; Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis.
J Biol Chem ; Activated protein C: biased for translation. Blood ; Activated protein C, protease activated receptor 1, and neuroprotection. Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke. Activated protein C inhibits tissue plasminogen activatorinduced brain hemorrhage. Nat Med ; An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischemic stroke in rodents.
Curr Pharm Des ; Final results of the RHAPSODY trial: a multi-center, phase 2 trial using a continual reassessment method to determine the safety and tolerability of 3K3A-APC, a recombinant variant of human activated protein c, in combination with tissue plasminogen activator, mechanical thrombectomy or both in moderate to severe acute ischemic stroke.
Ann Neurol ; Fingolimod for the treatment of intracerebral hemorrhage: a 2-arm proof-of-concept study. JAMA Neurol ; FTY ameliorates acute ischemic stroke in mice by reducing thrombo-inflammation but not by direct neuroprotection. Combination of the immune modulator fingolimod with alteplase in acute ischemic stroke: a pilot trial.
Fingolimod enhances the efficacy of delayed alteplase administration in acute ischemic stroke by promoting anterograde reperfusion and retrograde collateral flow. SP shows neuroprotective effects and improves cognitive impairment in ischemic brain injury through NMDA receptor. Pharmacol Biochem Behav ; SP reduces oxidative stress via SOD activity and behavioral deficit in cerebral ischemia.
Therapeutic efficacy and pharmacological mechanisms of sp for treatment of cerebral ischemia. Stroke ;46 Suppl 1 :ATP Extension of therapeutic time window of tissue plasminogen activator with sp combination therapy in rat embolic stroke models. Quickly restoring blood flow to the brain is critical in the event of ischemic stroke, when an obstruction develops in a blood vessel supplying the brain. Both medications and procedures may be used to remove the blockage.
Restoring Blood Flow This image shows how applying clot-dissolving drugs like tPA directly to a blockage intra-arterial thrombolytic therapy or removing the clot with a special device can restore blood flow to the brain. Studies have shown that thrombolytic drugs, or clot-busters, effectively stop ischemic strokes and improve patient outcomes if specialists trained in giving the drugs are immediately available.
Ischemic strokes are the most common type of stroke and are caused by blockage of an artery. The most widely known and the only FDA-approved drug for treatment of ischemic stroke — intravenous tPA tissue plasminogen activator — can reverse stroke if given to carefully selected patients within a few hours of stroke onset. Neuro-interventional treatments offered at Froedtert hospital can expand the treatment window to 24 hours and beyond in some cases.
This means a high percentage of appropriate patients can receive tPA or a procedure to open a blocked blood vessel. Our stroke team has successfully used tPA since , and actively teach other hospitals how to safely administer this drug. Other new advances in stroke treatment are available, including minimally invasive procedures to restore blood flow to the brain.
These procedures may remove clots, prop arteries open carotid artery stenting and apply clot-dissolving drugs directly to the blockage intra-arterial thrombolytic therapy. During the first few hours following an ischemic stroke, intravenous tissue plasminogen activator IV tPA and other drugs may be used in select patients to remove or dissolve clots. The drug restores some blood flow to the heart in most people. However, the blood flow may not be completely normal and there may still be a small amount of muscle damaged.
Further therapy, such as cardiac catheterization with angioplasty and stenting, may be needed. Your health care provider will base the decisions about whether to give you a thrombolytic medicine for a heart attack on many factors. These factors include your history of chest pain and the results of an ECG test.
Most strokes are caused when blood clots move to a blood vessel in the brain and block blood flow to that area. For such strokes ischemic strokes , thrombolytics can be used to help dissolve the clot quickly.
Giving thrombolytics within 3 hours of the first stroke symptoms can help limit stroke damage and disability. As in heart attacks, a clot-dissolving drug isn't usually given if you have one of the other medical problems listed above. Thrombolytics are not given to someone who is having a stroke that involves bleeding in the brain.
They could worsen the stroke by causing increased bleeding. This risk is the same for both stroke and heart attack patients. If thrombolytics are felt to be too dangerous, other possible treatments for clots causing a stroke or heart attack include:.
0コメント